BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) delivery of peptides and proteins. It is a cutting-edge and mature solution for oral formulations not only for peptides, but also small molecules, novel protein scaffolds, nucleotides, domain antibodies.
Products, services, technology
Key products for outlicensing are sublingual products as exenatide, liraglutide, insulin+, and low dose sublingual IL2 for auto-immune disorders
BioLingus is open to partner its platform technology for development of products with other companies (eg peptides)